← Leaderboards
Babu L Tekwani
University Of Mississippi
$3,380,368
Attributed
$3,380,368
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2017–21$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$3,380,368 · 2
By mechanism
R01$2,792,396 · 1
R21$587,972 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Mississippi
Same institution · by research overlap
- Soumyajit Majumdar$5,403,793
- Larry A Walker$14,499,766
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsResistanceIn VivoParasitesPlasmaPropertyEvaluationIn VitroMedicalOralDrug Or Chemical Tissue DistributionPharmacologic SubstanceAffectBiological AvailabilityCytotoxicityDrug KineticsFormulationGlobal HealthDoseLeadMetabolismMouse ModelAnalogRodent
Grant awards (6)
New Drug Leads for Resistant Visceral Leishmaniasis$269,027
R21 · FY2021 · AI · contact PI
Nano-carrier Formulations for Targeted Drug Delivery and Malaria Radical Cure$728,482
R01 · FY2020 · AI · contact PI
New Drug Leads for Resistant Visceral Leishmaniasis$318,945
R21 · FY2020 · AI · contact PI
Nano-carrier Formulations for Targeted Drug Delivery and Malaria Radical Cure$742,840
R01 · FY2019 · AI · contact PI
Nano-carrier Formulations for Targeted Drug Delivery and Malaria Radical Cure$740,535
R01 · FY2018 · AI · contact PI
Nano-carrier Formulations for Targeted Drug Delivery and Malaria Radical Cure$580,539
R01 · FY2017 · AI · contact PI